 |
Yuma has been awarded three biotechnology grants from the ADDF to identify disease-modifying drug candidates for treating Alzheimer’s disease. The support of the ADDF has enabled Yuma to advance its lead program to treat proteinopathies. The partnership with the ADDF also benefits Yuma through access to the ADDF’s extensive network of scientific experts in AD. For more information on the ADDF, please visit http://www.alzdiscovery.org |
| The Laboratory for Drug Discovery in Neurodegeneration (LDDN), Brigham and Women’s Hospital (BWH) | Yuma had a productive five-year discovery partnership with the LDDN, during which a number of promising novel small molecules for treating proteinopathies were discovered. |
| The National Institutes of Health (NIH) and National Institute on Aging (NIA) | Yuma’s discovery work has been supported by the Small Business Technology Transfer (STTR) Phase 1 and 2 grants from the NIH-NIA.The National Institutes of Health (NIH) and National Institute on Aging (NIA). |
yumatestcom.wordpress.com 